Europe's Weight Loss Market Just Got a Whole Lot More Interesting The regulatory approval of Eli Lilly's oral GLP 1 drug, forglipron (brand name Foundayo), by Britain's Medicines and Healthcare Products Regulatory Agency marks a significant milestone in the European weight loss market.
This development has far reaching implications for patients, manufacturers, and healthcare systems alike.
The Convenience Revolution Foundayo's approval is notable not only because it clears the way for Eli Lilly to enter the European market but also because it offers a novel approach to weight management.